RAMP, NCT04179396: Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients |
|
|
| Completed | 1b | 8 | US | Rucaparib, Rubraca, CO-338, Enzalutamide, Xtandi, Abiraterone, Zytiga | zr Pharma & GmbH | Metastatic Castration Resistant Prostate Cancer | 11/21 | 01/23 | | |
NCI-2018-00438, NCT03552471: Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
|
|
| Active, not recruiting | 1 | 25 | US | Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, IMGN853, M9346A-sulfo-SPDB-DM4, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Rucaparib Camsylate, 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt, C0-338, Rubraca, Rucaparib Phosphate | Ohio State University Comprehensive Cancer Center, ImmunoGen, Inc., Clovis Oncology, Inc. | BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer | 06/22 | 12/23 | | |
